The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

Abstract Background A multi-biomarker disease activity (MBDA) score has been validated as an objective measure of disease activity in rheumatoid arthritis (RA) and shown to track response to treatment with several disease-modifying anti-rheumatic drugs (DMARDs). The objective of this study was to ev...

Full description

Bibliographic Details
Main Authors: Nadia M. T. Roodenrijs, Maria J. H. de Hair, Gill Wheater, Mohsen Elshahaly, Janneke Tekstra, Y. K. Onno Teng, Floris P. J. G. Lafeber, Ching Chang Hwang, Xinyu Liu, Eric H. Sasso, Jacob M. van Laar
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Disease activity
Treatment response
MBDA score
Biomarkers
Rituximab
Online Access:http://link.springer.com/article/10.1186/s13075-018-1750-5

Internet

http://link.springer.com/article/10.1186/s13075-018-1750-5

Similar Items